Sign In
Buy IMMP
$0.407
-0.0093 (-2.24%)
At Close: Jun 03, 2026
Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
08:00am, Monday, 22'nd Dec 2025
SYDNEY, AUSTRALIA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune d
Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
08:00am, Tuesday, 16'th Dec 2025
The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial's targeted enrolment Strong operational progress continues globally with over 120 activated clinical si
Dr. Reddy's receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront
India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug
02:34am, Monday, 08'th Dec 2025
Indian drugmaker Dr Reddy's signed an exclusive licensing pact with Australia's Immutep to manufacture, develop and distribute the latter's cancer therapy, the companies said on Monday.
SYDNEY, AUSTRALIA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune d
SYDNEY, AUSTRALIA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmun
Immutep Quarterly Activities Report Q4 FY25
08:00am, Wednesday, 30'th Jul 2025
Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
08:00am, Tuesday, 29'th Jul 2025
SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune d
Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
08:00am, Tuesday, 27'th May 2025
SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune di
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo
03:50pm, Thursday, 15'th May 2025
Immutep Limited IMMP on Thursday announced additional data from the investigator-initiated INSIGHT-003 trial evaluating a triple combination therapy in front-line non-small cell lung cancer patients
Immutep Limited: Surging On Positive Head And Neck Data
08:46am, Thursday, 08'th May 2025
Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is we
Immutep to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 02'nd Apr 2025
SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmu
Immutep Quarterly Activities Report Q2 FY25
08:00am, Friday, 31'st Jan 2025
Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature d
Immutep Limited: Continuing To Make The Case For Eftilagimod
04:37pm, Tuesday, 28'th Jan 2025
Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics. Key trials for eftilagimod show encouraging results, parti
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
08:00am, Tuesday, 17'th Dec 2024
SYDNEY, AUSTRALIA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunoth
